Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BeOne Medicines's enterprise value is $31,250 Mil.
BeOne Medicines's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $906 Mil. Therefore, BeOne Medicines's EV-to-EBITDA for today is 34.49.
The historical rank and industry rank for BeOne Medicines's EV-to-EBITDA or its related term are showing as below:
ONC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -666.84 Med: -11.6 Max: 225.34
Current: 34.49
During the past 13 years, the highest EV-to-EBITDA of BeOne Medicines was 225.34. The lowest was -666.84. And the median was -11.60.
ONC's EV-to-EBITDA is ranked worse than 78.37% of 416
companies
in the Biotechnology industry
Industry Median: 11.905
vs ONC: 34.49
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BeOne Medicines's PE Ratio (TTM) for today is calculated as:
BeOne Medicines's share price for today is $316.01.
BeOne Medicines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.290.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for BeOne Medicines's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BeOne Medicines's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's EV-to-EBITDA falls into.
BeOne Medicines's current Enterprise Value is $31,250 Mil.
BeOne Medicines's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $906 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines (ONC) has a EV-to-EBITDA of 34.49 as of Aug. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BeOne Medicines. According to the industry distribution chart, BeOne Medicines ranks #326 out of 416 companies in the Biotechnology industry, placing it in the top 78.4%.
Is BeOne Medicines' EV-to-EBITDA too high?
BeOne Medicines' current EV-to-EBITDA is 34.49. The Biotechnology industry median EV-to-EBITDA is 11.91. BeOne Medicines' value of 34.49 is 189.7% above this industry median. Based on the distribution chart, BeOne Medicines ranks #326 out of 416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BeOne Medicines has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' EV-to-EBITDA compare to ALNY and RVMD?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #326 out of 416 companies for EV-to-EBITDA. This places BeOne Medicines in the lower half of its industry. The industry median EV-to-EBITDA is 11.91. BeOne Medicines' value of 34.49 is 189.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.91, based on 416 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BeOne Medicines's current EV-to-EBITDA of 34.49 is 189.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BeOne Medicines. For the Biotechnology industry, the median EV-to-EBITDA is 11.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeOne Medicines's current EV-to-EBITDA is 34.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $372.15, compared to a current price of $316.01 — trading 15.1% below its estimated fair value. The current EV-to-EBITDA is 34.49 and 189.7% above the Biotechnology industry median of 11.91. BeOne Medicines' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For BeOne Medicines (ONC), the current EV-to-EBITDA is 34.49 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (ONC) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of $316.01 is trading 15.1% below its estimated GF Value™ of $372.15.
GuruFocus considers BeOne Medicines to be Modestly Undervalued.
Key valuation signals for ONC:
EV-to-EBITDA: 34.49
GF Value™: $372.15 vs. price of $316.01 (15.1% below fair value)
Industry Position: 189.7% above the Biotechnology median (#326 of 416)
No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
77GF Score
Get the complete analysis for ONC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONC has been successfully added to your 
